The outlook and analysis of Aligos Therapeutics Inc (ALGS)’s stock

At the time of writing, Aligos Therapeutics Inc [ALGS] stock is trading at $0.98, down -4.02%. An important factor to consider is whether the stock is rising or falling in short-term value. The ALGS shares have gain 2.73% over the last week, with a monthly amount glided 3.05%, and seem to be holding up well over a long-time horizon.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

On 27, March 2024, Aligos Therapeutics Presents Positive Clinical Data at APASL 2024 from ALG-055009 and ALG-000184 Phase 1 Studies. In a post published today on Yahoo Finance, Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today announced three oral presentations and one poster presentation at the 33rd Annual Meeting of the Asian Pacific Association for the Study of the Liver (APASL) 2024, being held March 27-31, 2024 in Kyoto, Japan.

From an analyst’s perspective:

Aligos Therapeutics Inc [NASDAQ: ALGS] stock has seen the most recent analyst activity on January 06, 2023, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $3 from $2. Previously, Jefferies upgraded its rating to Buy on January 06, 2023, and elevated its price target to $3. On March 23, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $4 on the stock. JP Morgan downgraded its rating to a Neutral and decreased its price target to $12 on January 07, 2022. Jefferies downgraded its rating to a Hold. SVB Leerink started tracking with a Outperform rating for this stock on September 09, 2021, and assigned it a price target of $29.

For the past year, the stock price of Aligos Therapeutics Inc fluctuated between $0.54 and $1.38. Currently, Wall Street analysts expect the stock to reach $3 within the next 12 months. Aligos Therapeutics Inc [NASDAQ: ALGS] shares were valued at $0.98 at the most recent close of the market. An investor can expect a potential return of 206.12% based on the average ALGS price forecast.

Analyzing the ALGS fundamentals

According to Aligos Therapeutics Inc [NASDAQ:ALGS], the company’s sales were 15.53M for trailing twelve months, which represents an -24.20% plunge. Gross Profit Margin for this corporation currently stands at 0.8% with Operating Profit Margin at -5.55%, Pretax Profit Margin comes in at -5.59%, and Net Profit Margin reading is -5.65%. To continue investigating profitability, this company’s Return on Assets is posted at -0.57, Equity is -1.16 and Total Capital is -0.66. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.12.

Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 0.9395 points at the first support level, and at 0.9001 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.0192, and for the 2nd resistance point, it is at 1.0595.

Aligos Therapeutics Inc [ALGS] reported earnings per share of -$0.22 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.27/share, meaning a difference of $0.05 and a surprise factor of 18.50%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were -$0.41 per share as compared to estimates of -$0.47 per share, a difference of $0.06 representing a surprise of 12.80%.

Ratios To Look Out For

It is important to note that Aligos Therapeutics Inc [NASDAQ:ALGS] has a current ratio of 5.90. On the other hand, the Quick Ratio is 5.90, and the Cash Ratio is 5.68. Considering the valuation of this stock, the price to sales ratio is 4.77, the price to book ratio is 0.80.